Navigation Links
MedThink Communications Retained by NanoBio Corporation
Date:9/4/2007

RALEIGH, N.C., Sept. 4 /PRNewswire/ -- MedThink Communications, an innovator in health care communications and public relations, has been retained by NanoBio Corporation to promote its novel technology that uses nano-sized particles to eradicate skin infections, without harming normal tissue.

MedThink will implement a scientifically based communications program that includes public relations, advocacy development and medical communications in order to advance NanoBio's lead products, two topical agents (NB-001 and NB-002) that safely treat cold sores and toenail fungus.

"The depth of our scientific expertise allows us to transform highly technical information into readily understandable messages that resonate with a company's key audiences," said Scott Goudy, partner at MedThink. "Our scientific staff works in tandem with the promotional and public relations teams to build a comprehensive, integrated communications program."

NanoBio's scientific platform is in various stages of testing for skin infections, shingles, eye infections, vaginitis, genital herpes, and mucosal vaccines against influenza and hepatitis B. The mucosal vaccines, delivered nasally, will carry antigens that serve to alert and rouse the immune system into action against each respective infection. In the future, NanoBio plans to apply its technology to other mucosal vaccines that may include tuberculosis, small pox, anthrax and other viral and bacterial diseases.

ABOUT MEDTHINK COMMUNICATIONS

MedThink Communications is an award-winning, full-service medical agency whose communication services capture the essence of your brand and transform it into compelling messages that inspire your target audiences. Our innovative approach to advertising, medical communications, public relations, media planning and placement, sales training and marketing consulting serves as the perfect complement to strengthen our health care partners' competitive edge. (http://www.medthink.com)

ABOUT NANOBIO

NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines, based on its patented NanoStat(TM) technology platform. Founded in 2000 as a spin-out from the Center for Biologic Nanotechnology at the University of Michigan, NanoBio's lead product candidates target treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and mucosal vaccines for hepatitis B and influenza. The company's pipeline also includes products that target genital herpes, herpes zoster (shingles) and methicillin-resistant Staphylococcus aureus (MRSA).


'/>"/>
SOURCE MedThink Communications
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Physician and Patient relationship strained due to non-verbal communications
2. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Dr. Poneh Ghasri, cosmetic ... treatments to both new and existing patients. Cosmetic dentistry allows patients to improve the ... have healthy smiles with some minor or more serious cosmetic flaws. These specials allow ...
(Date:5/3/2016)... ... May 03, 2016 , ... Celestix ... announced the new SecureAccess feature for its CelestixEdge solution. CelestixEdge is the ... enable organizations to get the DirectAccess user experience on unsupported DirectAccess clients ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... helps healthcare organizations, especially medium and small physician practices, to better grasp and ... unique step-by-step approach that guides practices on a well-defined, expert-created path to compliance. ...
(Date:5/2/2016)... ... May 03, 2016 , ... RNK Products, Inc. (RNK) ... software that enables the stethoscope stream to go over the video conferencing audio ... flagship PCP-USB stethoscope. , Remote auscultation involves two software elements on the PC: ...
(Date:5/2/2016)... ... May 02, 2016 , ... The ... Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused on research ... issue representing international (non-US) based authors, the third volume of PXJ continues to ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... NEW YORK , May 2, 2016 ... the EMR (Electronic Medical Records) market in a recent ... International sales, vendor switches, Increased physician usage, a growing market ... trends were noted in Kalorama,s report EMR ... The report marks Kalorama,s seventh complete study of the ...
(Date:5/2/2016)...  Celsion Corporation (NASDAQ: CLSN ), an ... the first cohort of patients in its Phase ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... the first three patients dosed, GEN-1 plus standard ...
(Date:4/29/2016)... April 29, 2016 Acquisition ... Sciences, Product Development Capabilities in North ... Base . Indegene ( http://www.indegene.com ... the acquisition of Skura Corporation,s life science business. ... adaptive sales enablement technology for life science organizations ...
Breaking Medicine Technology: